LTBP4

Across TCGA pan-cancer cohorts, LTBP4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated LTBP4 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher LTBP4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LTBP4 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, PDAC, and UCEC are the cancer types where LTBP4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	II,III,IV	0.831	0.964	.021	35	view →
PDAC	OS	Median	All	0.633	0.440	.004	16	view →
UCEC	OS	Median	II,III,IV	0.620	1.000	.011	12	view →
LUAD	DFS	Median	II,III,IV	0.747	0.959	.001	12	view →
GBM	DFS	Tertile	All	0.292	0.483	.017	6	view →
LSCC	DFS	Quartile	II,III,IV	0.790	1.000	.023	5	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

LTBP4–CCRCC (DFS)

Open the CCRCC breakdown →